Rilzabrutinib: BTK Inhibition in Warm Autoimmune Hemolytic Anemia

Updated on March 20,2026|Written by Patsnap Team

On February 9, 2026, the FDA granted Breakthrough Therapy designation to Rilzabrutinib (Sanofi) for the treatment of warm autoimmune hemolytic anemia (wAIHA) — making it the first BTK inhibitor to receive this designation for this indication. The drug is currently in a pivotal Phase 3 trial (LUMINA 3, NCT07086976), with a mechanism that differentiates it structurally from first-generation irreversible BTK inhibitors.

All pipeline, patent, and competitive data cited here is sourced from Patsnap Synapse.

Snapshot

The Indication: Warm Autoimmune Hemolytic Anemia

Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disorder in which IgG autoantibodies bind red blood cell surface antigens at physiological body temperature (~37°C). The autoantibody-coated red blood cells are recognised by Fc receptors on splenic macrophages and destroyed prematurely — a process called extravascular hemolysis — leading to anemia, fatigue, pallor, jaundice, and in severe cases, life-threatening hemodynamic compromise.

wAIHA has an estimated annual incidence of 1–3 cases per 100,000 individuals and accounts for approximately 70–80% of all autoimmune hemolytic anemia cases. It may occur idiopathically or secondary to lymphoproliferative diseases (CLL, lymphoma), autoimmune conditions (SLE), infections, or medications.

Current standard of care consists of corticosteroids as first-line therapy, with rituximab (anti-CD20), splenectomy, and immunosuppressants used in refractory or relapsed disease. Rituximab produces responses in approximately 70–80% of patients but is not universally effective, and long-term remission rates remain suboptimal. For disease background, see NORD’s wAIHA entry.

The Target: BTK (Bruton’s Tyrosine Kinase)

BTK is a non-receptor tyrosine kinase of the Tec family, expressed in B cells and myeloid lineage cells. Its domain architecture — PH domain (membrane localisation via PIP3 binding), TH domain, SH3, SH2, and kinase (SH1) domain — allows precise regulation of its activation by upstream PI3K signalling.

In B-cell receptor (BCR) signalling, BTK is recruited to the plasma membrane and phosphorylated by LYN and SYK following antigen engagement, leading to activation of PLCγ2, calcium mobilisation, and downstream NF-κB, MAPK, and NFAT activation — driving B-cell proliferation, differentiation, and immunoglobulin production.

In wAIHA, autoreactive B cells produce pathogenic IgG autoantibodies via BTK-dependent BCR signalling. BTK inhibition is therefore a mechanistically rational approach to suppress autoantibody production at source.

Tracking the full BTK competitive landscape — 386 drugs across indications, development stages, and patent families? Search BTK on Patsnap Synapse →

What Makes Rilzabrutinib Different: Covalent Reversible Mechanism

First-generation BTK inhibitors — ibrutinib, acalabrutinib, zanubrutinib — are covalent irreversible inhibitors. They form a permanent covalent bond with the C481 residue in BTK’s ATP-binding site. While highly effective in B-cell malignancies, irreversible inhibition has been associated with off-target covalent binding to other kinases (ITK, TEC, EGFR), contributing to adverse effects including atrial fibrillation, bleeding, and rash. The C481S mutation also confers resistance to this class.

Rilzabrutinib is a covalent reversible BTK inhibitor — it forms a transient covalent bond with C481 that can be released, providing high BTK selectivity while reducing the off-target covalent engagement seen with irreversible agents. This mechanism theoretically improves the therapeutic index for autoimmune indications, where long-term tolerability is critical and patients may be less willing to tolerate the adverse effects associated with oncology-focused BTK inhibitor dosing.

Want to track the full competitive landscape, patent estate, and clinical pipeline for this target? Search this target on Patsnap Synapse →

Clinical Development

According to Synapse, rilzabrutinib has 29 clinical trials on record across indications. The wAIHA program represents the most advanced autoimmune application:

The Breakthrough Therapy designation for wAIHA was granted based on preliminary clinical data from earlier-phase studies demonstrating meaningful hemoglobin improvements in wAIHA patients. Sanofi’s February 9 announcement — covered in the official GlobeNewswire press release — noted simultaneous Orphan Drug designation in Japan.

Patent Estate

Synapse identifies 178 patents covering rilzabrutinib, spanning:

• Core compound patents — pyrrolopyrimidine scaffold with covalent reversible binding moiety targeting BTK C481
• Synthesis and process patents — manufacturing routes for the active pharmaceutical ingredient
• Formulation patents — oral tablet formulations and bioavailability optimisation
• Method of treatment patents — use in B-cell mediated autoimmune diseases including pemphigus, ITP, and wAIHA
• Combination therapy patents — rilzabrutinib in combination with anti-CD20 agents and corticosteroids

Competitive Landscape

Synapse identifies 386 drugs currently targeting BTK across all indications. Within the autoimmune-specific BTK inhibitor space — distinct from the larger B-cell malignancy segment — the competitive field is less crowded but rapidly developing:

Rilzabrutinib’s Breakthrough Therapy designation gives it a regulatory head start in the wAIHA field. If LUMINA 3 reads out positively, it would be the first BTK inhibitor with a formal approval in a primary autoimmune hematological indication.

What to Watch

• LUMINA 3 readout — the pivotal Phase 3 trial. Primary endpoint is likely hemoglobin response rate; timing of interim and primary analyses has not been publicly announced.
• Regulatory submission timeline — given Breakthrough Therapy status, rolling NDA review is possible once sufficient data accrues.
• Combination with anti-CD20 — whether rilzabrutinib + rituximab outperforms monotherapy in wAIHA is an open question that may be explored in supplementary cohorts.

Monitor competitor pipeline movements and patent expiry timelines before anyone else with Patsnap Synapse. Get started →

Patsnap Synapse maps rilzabrutinib’s 178 patents, 29 clinical trials, and full BTK competitive landscape in one platform — updated in real time. Explore rilzabrutinib on Synapse →

Monthly drug approvals, ERP designations, competitor pipeline shifts — Patsnap Synapse helps drug development and BD teams stay ahead of the curve. Request a demo →

Further Reading

• Global drug approvals roundup — February 2026
• Breakthrough Therapy designations — February 2026
• What is BTK? Target biology, inhibitor classes, and clinical applications
• FDA expedited pathways explained: Accelerated Approval, Breakthrough Therapy, Priority Review

Data sourced from Patsnap Synapse. This post is for informational purposes only and does not constitute clinical or investment advice.